Curriculum
Vitae
October 24, 2006 Joseph Gregory Liberto, M.D. Associate Professor of Psychiatry Baltimore VA Medical Center Psychiatry Service 10 North Greene Street Baltimore, Maryland 21201 Phone: Born: Citizenship:
(410)-605-7368 January 3, 1960, Baltimore, Maryland USA
EDUCATION 1982
B.S., Loyola College, Baltimore, Maryland
1986
M.D., University of Maryland Medical School Baltimore, Maryland
INTERNSHIP AND RESIDENCY (Psychiatry) 1986-1990
University of Maryland at Baltimore Department of Psychiatry Baltimore, Maryland
CERTIFICATIONS 1991
Diplomate, American Board of Psychiatry and Neurology #34718
1993,2002
American Board of Psychiatry and Neurology certification in the medical subspecialty of Psychiatry with Added Qualifications in Addiction Psychiatry
1994
American Board of Psychiatry and Neurology certification in the medical subspecialty of Psychiatry with Added Qualifications in Geriatric Psychiatry (Currently Not Active)
LICENSURE Maryland, #D35946 MAJOR RESEARCH INTERESTS Addiction Medication Trials
Addiction in the Elderly Alcoholism and Drug Abuse Service Care Delivery
FACULTY POSITIONS 1990-1991
Clinical Instructor, Department of Psychiatry University of Maryland School of Medicine
1991-1993
Clinical Assistant Professor, Department of Psychiatry University of Maryland School of Medicine
1993-2000
Medical School Assistant Professor, Department of Psychiatry University of Maryland School of Medicine
2000-present
Associate Professor, Department of Psychiatry University of Maryland School of Medicine
MAJOR PROFESSIONAL/ACADEMIC TASKS Current: 1998- present
Residency (Fellowship) Training Director, Addiction Psychiatry Residency (Fellowship), University of Maryland, Department of Psychiatry
1998 – present
Member, Mental Health Executive Committee (MHEC), Mental Health Clinical Center, VA Maryland Health Care System
1999- present
Member, VAMHCS Professional Standards Board
1999-
Member, American Board of Psychiatry and Neurology, Committee for Added Qualifications in Addictions
present
2004- present
Substance Use Disorder (SUD) QUERI, Executive Committee member
2005- present
Acting Lead Psychiatrist, Mental Health Clinical Center, VA Maryland Health Care Center
2005- present
Co-Chairman, VHA Substance Use Disorder QUERI (SUD) Buprenorphine Work Group
2005- present
Vice President, Board of Directors, American Academy of Addiction Psychiatry (AAAP)
Past: 1990-1999
Medical Director, Special Populations Substance Abuse Treatment Program, Baltimore VAMC
1991-1996
Chief, Substance Abuse Treatment Program, Baltimore VAMC
1993-1998
Chairman, GY1 Curriculum Committee University of Maryland, Department of Psychiatry
1995-1997
Chairman, Psychiatry Residency Evaluations Committee, University of Maryland, Department of Psychiatry
1995-1998
Associate Fellowship Training Director, Addiction Psychiatry Fellowship, Division of Alcohol and Drug Abuse, University of Maryland, Department of Psychiatry
1995-1998
Assistant Chief of Psychiatry Primarily Responsible for Addiction Services Baltimore VAMC
1996- 2002
Clinical Manager, Addiction Treatment Program, VA Maryland Health Care System
1997- 1999
Area III Director, American Academy of Addiction Psychiatry
1997- 2000
Member, VA Task Force (Substance Abuse Work Group) for the Development of Clinical Guidelines for Treatment of Patients with Substance Abuse
1998- 2000
Associate Director of Graduate Education, University of Maryland, Department of Psychiatry
1998- 2003
Associate Director of Post-Graduate Education, University of Maryland, Department of Psychiatry
1998 – 2004
Member, Educational Directorate, University of Maryland, Department of Psychiatry, School of Medicine
1998- 2005
Member representing Substance Abuse Treatment Services, VISN 5 Mental Health Leadership Committee
1999
Ad Hoc Task Oriented Subcommittee Chair on Office Based Opioid Treatment, American Academy of
Addiction Psychiatry 1999-
2001
Head, Policy Section: Board of Directors, American Academy of Addiction Psychiatry
2000- 2002
Clinical Core Director, VISN 5 Mental Illness Research, Education and Clinical Center (MIRECC)
2001- 2002
Member, VAMHCS MHSL PI Counsel representing the VISN 5 MIRECC.
2001 – 2006
Secretary: Board of Directors, American Academy of Addiction Psychiatry
2002- 2005
Clinical Manager: Special Programs: Trauma and Addiction Treatment Programs, VA Maryland Health Care System
2002
Organized American Board of Psychiatry and Neurology Part II oral Board Examinations at the Baltimore VAMC site, September 30, October 1st, 2002
2003- 2005
VAMHCS Mental Health Service Line Liaison with the University of Maryland Psychiatry Residency Training Program, Department of Psychiatry, University of Maryland, School of Medicine
PROFESSIONAL MEMBERSHIP American Psychiatric Association Maryland Psychiatric Society American Academy of Addiction Psychiatry HONORS/AWARDS 1981
Membership in Alpha Sigma Nu (Jesuit Honor Society)
1982
Carrel Biology Medal, Loyola College
1982
Magna Cum Laude, Loyola College
1983
Academic Honors- Fetal Developmental Anatomy and Histology
1983
Academic Honors- Gene Amplification Research Project
1985
Academic Honors- Psychiatry Clerkship
1989
Inpatient Chief Resident, University of Maryland Department of Psychiatry
1992
Department of Veterans Affairs Central Office Service Director's Award for Mental Health and Behavioral Sciences in recognition of achievement in enhancing clinical care
1996, 1997
Best Doctors in America: Southeast Region
1996
H. Mckee Jarboe Award for Mental Health Research
2003
Selected one of the “Best Doctors in America” in the “Guide to America’s Top Physicians”, 2003 Edition.
2005.2006
Selected for inclusion in “Best Doctors in America”.
EDITORIAL EXPERIENCE 1989- 2000
Reviewer, Psychiatric Services
1997
Field Reviewer, Treatment Improvement Protocol (TIP) Substance Abuse Among Older Adults developed under contract by the Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMSHA)
1997
Journal of Mental Health and Aging
2002
Journal of Substance Abuse Treatment Special Issue, Blending Practice and Research"
2003- present
Substance Abuse, Journal of the Association for Medical Education and research in Substance Abuse
2003
Peer Reviewer, Buprenorphine in the Treatment of Opioid Dependence (AAAP on-line Web-based course), Strain, E and Novey, J (Editors)
2005
Individual Reviewer, American Psychiatric Associations (APA)Practice Guideline for the Treatment of Patients With Substance Use Disorders, 2nd Addition
2006
MAJOR CONSULTANTSHIPS National:
Reviewer, Buprenorphine Training Course, American Academy of Addiction Psychiatry, E McCance-Katz (Editor)
1996-1997
Member, VA Task Force (The MDD Working Group) for the Development of Major Depressive Disorder (MDD), MDD with Post Traumatic Stress Disorder, and MDD with Substance Abuse and Substance Use Disorder Treatment Guidelines and Algorithms
1996-1998
Member, VA Task Force (The Psychosis Working Group) for the Development of Clinical Guidelines for Management of Persons with Psychoses (and Substance Abuse)
1997-2000
Member, VA Task Force (Substance Abuse Work Group) for the Development of Clinical Guidelines for Treatment of Patients with Substance Abuse
1998- 2004
Member, External Advisory Committee, VA Center of Excellence in Substance Abuse Treatment and Education (CESATE)
1998
Member, Federal Resource Panel, Office-Based Opioid Treatment, Center for Substance Abuse Treatment (CSAT)
2000
Member, National Advisory Council Accreditation Subcommittee, responsible for consulting and making recommendations on the accreditation process for narcotic substitution programs to the National Advisory Council (CSAT)
2000
Member, Buprenorphine Curriculum Panel Training Project, responsible for designing a curriculum for addiction medicine specialists as a prerequisite for prescribing buprenorphine as a treatment for opioid addiction (CSAT)
2000- 2003
Member representing AAAP, Coalition for Treatment of Alcoholism and Other Drug Dependencies, working to improve state parity for addiction treatment disorders.
2002
Member, CSAT Resource Panel on “Medication Assisted Treatment for Opioid Addiction�
2003-2004
Member, NIDA/VA Research Planning Group: Integrating Treatment with Buprenorphine and HAART
2005- present
TEACHING ACTIVITIES Current:
Member, Center for Substance Abuse Treatment (CSAT), Division of Pharmacologic Therapies, Accreditation Guidelines Expert Panel
1989-present
Group Instructor, Introduction to Clinical Practice Course/Physical Diagnosis, University of Maryland School of Medicine [This involves conducting an interviewing seminar with 4 to 6 medical students. Level of involvement has varied from year to year]
1990-present
Inpatient, outpatient and group therapy supervisor for GY1 through GY4 residents, University of Maryland, Department of Psychiatry [Level of involvement has varied from year to year]
1991-present
Geriatric Resident (Fellow) Supervision, Geriatric Addictions Clinic, University of Maryland, Department of Psychiatry [Level of involvement has varied from year to year]
1992-present
Addiction Psychiatry/Medicine Resident (Fellow) Supervision, VA Addiction Treatment Program, University of Maryland, Department of Psychiatry [Level of involvement has varied from year to year]
1992-present
Lecturer, "Alcoholism in the Older Population", Geropsychiatry Resident (Fellow) Conference, University of Maryland Department of Psychiatry
1993-present
Lecturer, "Levels of Care in Substance Abuse Treatment", PGY 2 Psychiatry Residents, University of Maryland Department of Psychiatry
1997-present
Lecturer,“Substance Abuse and Depression”,PGY-III Addiction Psychiatry Lecture Series, University of Maryland, Department of Psychiatry
1999-present
Lecturer, “Biology and Psychology of Alcoholism”, Advanced Academic Seminars, University of Maryland, Department of Psychiatry
2002- present
Lecturer, “Neurobiology of Addiction”: Neuroscience Course, Maryland Psychiatric Research Center
2002- present
Lecturer, PGY2 Lecture Series, “Treating Opioid Dependendent Patients with Buprenorphine” Residents, University of Maryland, Department of Psychiatry
Past:
1988-1993
Small Group Instructor, Sophomore Psychopathology Course, University of Maryland School of Medicine [Level of Involvement varied from year to year but generally about five to ten one our sessions per year with a small group of medical students]
1989
Group Instructor, Behavioral Social Science Course, University of Maryland Medical School
1989-1990
Coursemaster, Inpatient Strategies Course, University of Maryland Department of Psychiatry [Coordinated a series of lectures on inpatient treatment and taught lecture on “Aftercare Planning” to about twelve PGY1 Psychiatry Residents]
1990-1993
Educational Coordinator for Unit on Somataform Disorders, Sophomore Psychopathology Course, University of Maryland School of Medicine [Coordinated a series of lectures and taught on “Conversion Disorder” to approximately one hundred and twenty-five sophomore medical students]
1991-1996
Medical Student Clerkship Addiction Elective Supervision, University of Maryland, School of Medicine [Met with two to three medical students each week to discuss patient cases and topics related to addiction psychiatry]
1993-1998
Coursemaster, Issues at the Interface of Psychiatry and Medicine, University of Maryland Department of Psychiatry [Coordinated a series of six to eight one hour lectures to about twelve PGY1 residents. I was the discussant each week with the lectures given by non-psychiatrist physicians regarding basic medical management of patients likely to be seen in psychiatric settings]
1995-1996
"Addiction in the Elderly", VA Social Work Intern Lecture Series, University of Maryland, School of Social Work [Lectured two hours per year to about six social work interns rotating at the Baltimore VA from the University of Maryland, School of Social Work]
1996-2001
Coursemaster, Addiction in the Elderly, Addiction Advanced Academic Seminars, University of Maryland, Department of Psychiatry
1996-2004
Addiction Psychiatry Education and Case Conference for PGY1 and PGY2 residents doing their required addiction rotation
1997
Group Facilitator, Medical Student Pathophysiology and Therapeutics, Small Group No. 35, University of Maryland School of Medicine [Facilitated group discussion on addiction and comorbidity issues to a small group of medical students]
1998-2004
PGY1 and PGY2 Case Conferences
1998-2001
Lecturer and Coursemaster (1998-2000), Basic Diagnostic Interviewing, GY1 Psychiatry Residents, University of Maryland, Department of Psychiatry
2001, 2002
“Schizophrenia and Addiction”, Lecture to University of Maryland/VAMHCS Psychology Interns
GRANT SUPPORT Principal Investigator: 1991
Expansion/Enhancement of VA Alcohol, Drug and Substance Abuse Treatment Programs "Addiction Day Treatment Program" Awarded by VA Central Office Direct Costs Awarded: $217,000/year
1994
Cotinine in the Treatment of Nicotine Dependence: A Double Blind Controlled Trial (Liberto, J., Eichmiller, P, Johnson, J and Keenan, R) - $35,000 - Lec Tec Pharmaceuticals
1999
A Phase II Study Assessing Use of a Peripherally Selective mu Opioid Antagonist to Speed Gastrointestinal Transit in Methadone Dependent Patients with Opioid-Induced Constipation (Liberto, J., Jaffe J., Horvath K. and Rutherford R.) - $69,000 – Adolor Corporation
2000
Extension of A Phase II Study Assessing Use of a Peripherally Selective mu Opioid Antagonist to Speed Gastrointestinal Transit in Methadone Dependent Patients with Opioid-Induced Constipation (Liberto, J., Jaffe J., Horvath K. and Rutherford R.) - $19,010 – Adolor Corporation
2001
“Opioid Substitution Expansion Program”, Awarded by VA Central Office, $275,900 in Personnel Service Costs Awarded: year for 2 years. $37,000 awarded for all other costs.
2007
“Facilitators and Barriers to Implementing Buprenorphine Therapy for Treatment of Opioid Dependence” Awarded by VA HSR&D Liberto J. and Gordon A. (co PI) - $50,000
Co-investigator: 1993
L-Alpha Acetylmethadol (LAAM) Safety Study (Joseph Liberto, M.D. and Phil Eichmiller, M.S.W, M.P.H.,site co-site principal
investigators) - $46,000 VA / NIDA cooperative study 1993
HIV/AIDS Education Demonstration Project, "The Effect of Sex Partner Involvement in Safer Sex Education in Reducing Transmission of HIV Among Substance Abusers (Clare Kearns, L.C.S.W., Phil Eichmiller, M.S.W., M.P.H. and Joseph Liberto, M.D.) - $5,000 - VA Central Office
1994
Naltrexone in the Adjunctive Treatment of Older Age Alcoholics: A Double Blind Controlled Trial (Oslin, D., Liberto, J and O’Brien, J) - $30,000 - Dupont Pharmaceuticals
1994
HIV Vaccine in Seronegative IV Drug Users and Their Sexual Partners( Liberto, J. and Standiford, H. co-site Principal Investigators) - $4,000 - VA Central Office
1996
Buprenorphine/Naloxone CSP #1008 (Liberto, J, Principal site investigator) - $258,674VA/NIDA Cooperative Study
1999
Outpatient Selegiline Treatment for Cocaine Dependence (OUTSET) CSP# 1017 (Liberto, J, Principal site investigator) - $135,000- VA/NIDA Cooperative Study
1999
The Process of Change in Drug Abuse By Schizophrenics (Bellack, A., DiClemente, C., Scott, J., Liberto, J., Gearon, J.) - $1,754,171 - NIDA
2000
Double Blind, Placebo Controlled trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence CSP #1019 (Liberto, J Principal site investigator) - $309,604 – VA/NIDA Cooperative Study
2002
Multi-site Opioid Substitution Treatment Study, Liberto J (Site PI)
2003
Components of Effective Treatment for Dually Diagnosed Patients, Tiet, Q (PI), Liberto, J and Benson, Paul(site PIs) - $55,900
2004
Baclofen for the Treatment of Cocaine Dependence (Liberto, J. Principal Site Investigator VA/NIDA Cooperative Study –
PUBLICATIONS Chapters:
1995
Bartels S and Liberto J, “Dual Diagnosis in the Elderly”, Double Jeopardy: Chronic Mental Illness and Substance Use Disorders, Harwood Academic Publishers, Lehman A and Dixon L Editors
1996
Liberto J, Oslin D and Ruskin P, “ Alcoholism in the Older Population”, The Practical Handbook of Clinical Gerontology, Sage Publications, Carstensen L, Edelstein B, Dornbrand L, Editors,
1996
Oslin D and Liberto J, “Substance Use Disorders in the Elderly”, Psychiatry ed. Wilner, P, Philadelphia, JP Lipencott
1996
Liberto J, Oslin D, “Early Versus Late Onset of Alcoholism in the Elderly” Older Adults’ Misuse of Alcohol, Medicines, and Other Drugs, Springer Publications,Gurnack A, Editor
2001
Strain (Editor), Barthwell A., Brown, R, Darton, L., Fiellin, D., Kosten, T., Liberto, J., Manlandro, J., Ritvo, J., Vilensky, DO, RPh and Wesson, D., “Use of Buprenorphine in the Pharmacolgoic Management of Opioid Dependence A Curriculum for Physicians”, Development of the Curriculum supported by the: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services, January 2001
Journal Articles: Refereed: 1992
Liberto JG, Oslin DW, Ruskin PE: “Alcoholism in Older Persons: A Review of the Literature”, Hospital and Community Psychiatry, 43: 975-984, 1992
1994
Knowles FE, Liberto JG, Baker FM, Raskin, A Ruskin, PE: “Competency Evaluations in a VA Hospital: A 10-Year Perspective”, General Hospital Psychiatry,16(2): 119-124, 1994
1995
Liberto J, Oslin D, “Early Versus Late Onset of Alcoholism in the Elderly”, International Journal of the Addictions, 30(13&14),1799-1818, 1995
1997
Oslin D, Liberto J, OBrien J, Kroiss S: The Tolerability of Naltrexone in Treating Older Patients with Alcohol Dependence, American Journal of the Addictions, 6:266-270, 1997
1997
Oslin D, Liberto J, O’Brien J, Kroiss S:
Naltrexone as an Adjunctive Treatment for Older Patients with Alcohol Dependence, American Journal of Geriatric Psychiatry, 5:324-332, 1997 1998
Rothman RB, Gorelick PR, Eichmiller PR, Hill BH, Norbeck J and Liberto JG: An Open-Label Study of a Functional Opioid Kappa Antagonist in the Treatment of Opioid Dependence. Problems of Drug Dependence 1997. Proceedings of the 59th Annual Scientific Meeting, The College on Problems in Drug Dependence Meeting, Inc., NIDA Res. Monogr. No: 178: 309, 1998
2000
Rothman RB, Gorelick PR, Eichmiller PR, Hill BH, Norbeck J and Liberto JG: An Open-Label Study of a Functional Opioid Kappa Antagonist in the Treatment of Opioid Dependence. Journal of Substance Abuse Treatment, 18(3):277-281, 2000
2001
Welsh, CJ and Liberto J: The Use of Medication for Relapse Prevention in Substance Dependence Disorders, Journal of Psychiatric Practice, 7(1):15-31, 2001
2004
Welsh, C, Ghandi, D, Liberto, J and Weintraub, E: The role of diagnostic systems in the continued stigmatization of patients with opioid dependence, Psychiatric Services. 2004 Jan;55(1):86-7.
Reviews: 1996
Liberto J, Oslin D, "Commentary on the AMA Guidelines on Alcoholism in the Elderly: Diagnosis, Treatment, Prevention", Abstracts of Clinical Care Guidelines, JCAHO, 8(2): 9, 1996
Abstracts:
1995
Liberto J., Kroiss B, Keenan R, Rolf, D: “Cotinine in the Treatment of Cigarette Smoking” Journal of Addictive Diseases 14(3): 147, 1995 [Abstract]
1996
Oslin D; O'Brien J; Kroiss S, Liberto J, “The Safety of Naltrexone in Treating Older Patients with Alcohol Dependence", Alcoholism: Clinical and Experimental Research, 20:2, 1996 [Abstract]
2001
Liberto, JG, Herschler, JA, Jaffe JH, Norbeck JH and Carpenter RL, “Effects of ADL 8-2698, a peripherally restricted mu opioid antagonist, on gut motility in methadone and LAAM dependent patients with opioid-induced constipation: A
dose ranging study.” 2001 Annual CPDD Annual Meeting, Scottsdale, AZ. [Abstract]
POSTER PRESENTATIONS 1991
Kaup B, Liberto J, Ruskin P: “PTSD Symptoms in a Community Sample of World War II Veterans”, American Psychiatric Association Annual Meeting, 1991
1992
Meyer J, Knowles F, Liberto J: “Treatment Outcome After Competency Evaluation”, American Association for Geriatric Psychiatry Annual Meeting, 1992
1995
Liberto J, Kroiss B, Keenan R, Rolf, D, “Cotinine in the Treatment of Cigarette Smoking", American Society of Addiction Medicine 8th National Conference on Nicotine Dependence, Toronto, Ontario, Canada, October 1215, 1995
1996
Oslin DW; Liberto JG, O'Brien J; Kroiss S, The Safety of Naltrexone in Treating Older Patients with Alcohol Dependence", American Association for Geriatric Psychiatry 9th Annual Meeting, Tucson, Arizona, February 16-19, 1996
1996
Oslin DW; O'Brien J; Kroiss S, Liberto JG, The Safety of Naltrexone in Treating Older Patients with Alcohol Dependence", 1996 Joint Research Society on Alcoholism/International Society for Biomedical Research on Alcoholism Scientific Meeting, Washington, DC, June 22-27
1997
Oslin DW; Liberto JG, O'Brien J; Kroiss S, Norbeck J, “Naltrexone as an Adjunctive Treatment For Older Patients With Alcohol Dependence”, 1997 Annual meeting of the American Association for Geriatric Psychiatry, Orlando, FL, Febrary 1997
1997
Hayden TF, Libeto JG, Shearin E and Ruskin PE, “Clinical Implications of Comorbid Antisocial and Borderline Personality Disorders in Older Patients with Substance Use Disorders”, 1997 Annual Meeting of the American Psychiatric Association, San Diego, CA
1997
Rothman R, Gorelick D, Eichmiller P, Hill B, Norbeck J and. Liberto J, “An Open-Label Study of Functional Opioid Kappa Antagonist in the Treatment of Opioid Dependence”, 1997 Annual CPDD Annual Meeting, Nashville, TN
1998
Liberto J, Eichmiller P, An “In Treatment”
Versus “Out of Treatment” Comparison of Intravenous Drug Usage Rates in a Sample of Subjects at High Risk for HIV Infection, VISN 5 Research Day, Baltimore, MD 1999
Gearon JS, Bellack AS and Liberto JG, “Concurrent and Test-Re-test Reliability of the Addiction Severity Index and the Time Line Follow Back Among People with Schizophrenia”, 1999 International Congress on Schizophrenia Research
2003
Egwuagu, C., Eichmiller, P, West, N, Bodison, S, Bidwell, M, Robinson, J, Liberto, J, Blattner, W, Oursler, KA, “Potential Volunteer Populations for HIV-1 Preventive Trials: Differences in Demographics and Willingness to Participate”, University of Maryland Research Day, Baltimore Maryland, April 2003.
2003
Fareed, A, Benson, P, Liberto, J, “Predictable Factors for Completion of Outpatient Detoxification and Retention in Treatment, American Psychiatric Association Annual Meeting, San Francisco, Californian, May 2003.
INVITED SPEECHES/GRAND ROUNDS 1992
"The Baltimore VAMC Substance Abuse Treatment Program: a Model of Continuum of Care Treatment for Addicted Patients, Grand Rounds, Baltimore VAMC Psychiatry Service, Baltimore, MD
1994
"Diagnosing Alcoholism in the Elderly Patient", Grand Rounds, Perry Point VAMC, Psychiatry Service, Perry Point. MD
1994
"Addictions in Older Persons", The 2nd Annual Practical Approaches to Caring for the Elderly Conference, Frostburg State University, Maryland
1994
"Antabuse and Naltrexone in the Adjunctive Treatment of the Elderly Alcoholic", Grand Rounds, Perry Point VAMC, Psychiatry Service, Perry Point, MD
1995
"Case Discussion of a Patient with Treatment Refractory Depression and Amphetamine Dependence", Psychiatry Educational Rounds, Baltimore VAMC, Baltimore, MD
1995
“Baltimore VAMC Substance Abuse Treatment Program: A Continuum of Care”, Baltimore VAMC Educational Rounds, Baltimore, MD
1996
“Addiction Issues in the Elderly”, Geriatric Imperative Minimester,University of Maryland At Baltimore, Baltimore, MD
1996
“Update on the Recognition and Treatment of Addictions in Ambulatory Settings”, 1996 Semi Annual Meeting of the Medical and Chirurgical Faculty of Maryland, Ocean City, MD
1996
“Alcohol Abuse in Late Life”, Paper Session (Chair), November 20, Gerontologic Society of America Annual Meeting, Washington, DC
1996
“Psychopharmacologic Management of the Addicted Patient”, November 27, Grand Rounds, Kent and Queen Anne’s Hospital, Chestertown, MD
1996
“Update on the Identification and Treatment of Addictions in the Elderly”, December 4, Drug Treatment Center Educational Rounds, Carter Center, Baltimore, MD
1996
“Naltrexone in the Adjunctive Treatment of Alcoholism”, December 5, University of Maryland, Department of Psychiatry, Grand Rounds, Baltimore, MD
1997
“Identification and Treatment of Addiction in the Older Population”, February 19, University of Maryland, Department of Medicine Grand Rounds, Baltimore, MD
1997
“Naltrexone in the Adjunctive Treatment of Alcoholism”, March, Grand Rounds, Perry Point VA Department of Psychiatry, Perry Point, MD
1997
Content Expert, “Network Clinical Guidelines Implementation Program National Training Initiative”, Orlando, Florida
1998
“Alcoholism”, Community Health Beat Radio Talk Show, WEAA FM, August 20th, Baltimore, MD
1998
“Update on the Recognition and Treatment of Addiction in the Ambulatory Setting”, Perry Point VA Department of Psychiatry Grand Rounds, Perry Point, MD
2000
Discussant, “Buprenorphine Treatment: Research and Practice”,American Psychiatric Association Annual Meeting, May, Chicago, Illinois
2000
“Identification and Treatment of Addictions and Associated Psychiatric Comorbidities in Older Populations, Rehabilitation Services Department Rounds, Springfield State Hospital, September 13th Sykesville, Maryland
2000
“Smoking Cessation in VA Patients”, Smoking InService for Addiction Staff, VA Maryland Health Care System, Baltimore, Maryland September 28th, sponsored by the VISN 5 MIRECC
2000
“Smoking Service Maryland November
Cessation in VA Patients”, Smoking Infor Primary Care Staff Meeting, VA Health Care System, Baltimore, Maryland 29th, sponsored by the VISN 5 MIRECC
2000
“Use of Buprenorphine in the Pharmacological Management of Opioid Dependence: NonPharmacological Treatments, American Academy of Addicition Psychiatry Annual Meeting, December 8th, Phoenix Arizona
2000
“Use of Buprenorphine in the Pharmacological Management of Opioid Dependence: Psychiatric Comorbidity, American Academy of Addiction Psychiatry Annual Meeting, December 9th, Phoenix Arizona
2002
“Assessment and Screening in Office-Based Opioid Treatment”, Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence, March 22,Boston, Massachusetts
2002
“Special Populations in Office-Based Opioid Treatment”, Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence, March 22,Boston, Massachusetts
2002
“Maintenance and Detoxification in Office-Based Opioid Treatment”, Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence, March 22,Boston, Massachusetts
2002
“Special Populations in Office-Based Opioid Treatment”, 2002 San Antonio Buprenorphine Training, June 22,San Antonio, TX
2002
“Office Management in Office-Based Opioid Treatment”, 2002 San Antonio Buprenorphine Training, June 22,San Antonio, TX
2002
“Introduction and Summary of the Issues”, Double Trouble: Substance Abuse and Mental Illness Conference, Martinsburg West Virginia, September 23, 2002
2002
“Political Action and Building Coalitions” Workshop, American Academy of Addiction Psychiatry 13th Annual Meeting, December 13th 2002, Las Vegas, NV
2003
VA Healthwatch Cable TV Show #21. which aired starting April 2003.
2003
“Non Physician Buprenorphine Session”, Correctional Health Services Association ACHSA)Annual Conference, Baltimore Maryland, April 10, 2003
2003
Small Group Facilitator, ASAM Buprenorphine in Office Based Treatment of Opioid Dependence Training Course, Washington DC, April 12, 2003.
“Alcoholism”
2003
“Buprenorphine in the Office-Based Practice Workshop”, Maryland Addictions Directors Council Annual Conference, Ocean City, Maryland, May 15, 2003.
2003
“Agonist Treatment: Changing Landscape”, OfficeBased Treatment of Opioid Dependence with Buprenorphine Conference, Newark Delaware, June 2003
2003
“Patient Assessment/Selection”, Office-Based Treatment of Opioid Dependence with Buprenorphine Conference, Newark Delaware, June 2003
2003
“Psychiatric Morbidity”, Office-Based Treatment of Opioid Dependence with Buprenorphine Conference, Newark Delaware, June 2003
2003
“Clinical Management”, Office-Based Treatment of Opioid Dependence with Buprenorphine Conference, Newark Delaware, June 2003
2003
“Overview to Methadone, LAAM and Naltrexone”, “Efficacy and Safety of Buprenorphine”, Med Chi and the Maryland Health Commission, Baltimore, Maryland September 6th, 2003
2003
“Office Management, Confidentiality and Record Keeping”, “Psychiatric Co-morbidity” and “Special Treatment Populations”, Use of Buprenorphine in Pharmacologic Management of Opioid Dependence, Detroit Michigan, October 3rd, 2003
2003
Small Group Facilitator, ASAM Buprenorphine Training Course, Washington, DC November 2nd, 2003.
2004
“Office Based Treatment of Opioid Addiction with Buprenorphing”, Grand Rounds, Godd Samaritan Hospital, Baltimore, MD, January 21st, 2004.
2004
“Overview to Methadone, LAAM and Naltrexone”, “Efficacy and Safety of Buprenorphine”, Med Chi and the Maryland Health Commission, Baltimore, Maryland February 7th, 2004
2004
“General Opioid Pharmacology” and “Special Treatment Populations” for “Office-Based Treatment of Opioid Dependence” conference sponsored by the VISN 4 MIRECC, Pittsburgh, PA, scheduled 5/21/04 “General Opioid Pharmacology” and “Psychiatric CoMorbidity” for “Office-Based Treatment of Opioid Dependence” conference sponsored by the VISN 4 MIRECC, Philadelphia, PA, scheduled 6/4/04
2004
“The University of Maryland Residency Training Experience”, AAAP Workshop on Resident Education in the Addictions, American Academy of Addiction Psychiatry (AAAP) Anuual Meeting, San Juan Puerto Rico, December 2004
2005
“The University of Maryland Residency Training Experience”, AADPRT Workshop on Resident Education in the Addictions, American Association of Directors of Psychiatry Residency Training (AADPRT) Annual Meeting, Tucson, Arizona, March 2005
2005
Course Director and Lecturer for “Office-Based Treatment of Opioid Dependence” held in Savannah Georgia, April 23, 2005
2005
Course Director and Lecturer for “Office-Based Treatment of Opioid Dependence” held in Knoxville, Tennesee, May 21, 2005
2005
Lecturer for “Office-Based Treatment of Opioid Dependence” held in Indianapolis, Indiana, October 8, 2005
2006
Lecturer for “Office-Based Treatment of Opioid Dependence” held in Boston, Mass., April 8, 2006
2006
Course Director and Lecturer for “Office-Based Treatment of Opioid Dependence” held in West Palm, FL, May 20, 2006